Unknown

Dataset Information

0

Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a HSP90-dependent manner.


ABSTRACT: A peptide vaccine designed to induce T-cell immunity to telomerase, GV1001, has been shown to modulate cellular signaling pathways and confer a direct anti-cancer effect through the interaction with heat shock protein (HSP) 90 and 70. Here, we have found that GV1001 can modulate transactivation protein-mediated human immunodeficiency virus (HIV)-1 transactivation in an HSP90-dependent manner. GV1001 treatment resulted in significant suppression of HIV-1 replication and rescue of infected cells from death by HIV-1. Transactivation of HIV-long terminal repeat (LTR) was inhibited by GV1001, indicating that GV1001 suppressed the transcription from proviral HIV DNA. The anti-HIV-1 activity of GV1001 was completely abrogated by an HSP90-neutralizing antibody, indicating that the antiviral activity depends on HSP90. Further mechanistic studies revealed that GV1001 suppresses basal NF-?B activation, which is required for HIV-1 LTR transactivation in an HSP90-dependent manner. Inhibition of LTR transactivation by GV1001 suggests its potential to suppress HIV-1 reactivation from latency. Indeed, PMA-mediated reactivation of HIV-1 from latent infected cells was suppressed by GV1001. The results suggest the potential therapeutic use of GV1001, a peptide proven to be safe for human use, as an anti-HIV-1 agent to suppress the reactivation from latently infected cells.

SUBMITTER: Kim H 

PROVIDER: S-EPMC4929463 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a HSP90-dependent manner.

Kim Hong H   Choi Myung-Soo MS   Inn Kyung-Soo KS   Kim Bum-Joon BJ  

Scientific reports 20160701


A peptide vaccine designed to induce T-cell immunity to telomerase, GV1001, has been shown to modulate cellular signaling pathways and confer a direct anti-cancer effect through the interaction with heat shock protein (HSP) 90 and 70. Here, we have found that GV1001 can modulate transactivation protein-mediated human immunodeficiency virus (HIV)-1 transactivation in an HSP90-dependent manner. GV1001 treatment resulted in significant suppression of HIV-1 replication and rescue of infected cells f  ...[more]

Similar Datasets

| S-EPMC2761355 | biostudies-literature
| S-EPMC6663873 | biostudies-literature
| S-EPMC4805692 | biostudies-other
| S-EPMC4231758 | biostudies-literature
| S-EPMC3057569 | biostudies-literature
| S-EPMC3523124 | biostudies-literature
| S-EPMC6072277 | biostudies-literature
| S-EPMC7016760 | biostudies-literature
| S-EPMC3501896 | biostudies-literature
| S-EPMC4737163 | biostudies-literature